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OBJECTIVE: To compare the depression-related health
care expenditures among patients receiving mirtazapine,
venlafaxine XR and sertraline in a managed care setting.
METHODS: Pharmacy and medical claims were ob-
tained for patients in three major health plans, for three
months prior to and six months after their initiation of
antidepressant therapy. Patients included in the study
were 18 years or older; had a primary diagnosis of de-
pression; had no depression-related costs in the pre-index
period; had at least two prescriptions for the study anti-
depressant in the post-index period; were continuously
eligible during the study period, and had no claims for
substance abuse, schizophrenia or bipolar disorder. Cost
comparisons were estimated using multivariate regres-
sions after controlling for demographic and plan charac-
teristics.
RESULTS: Median depression-related costs after index
date for patients prescribed mirtazapine (n  182), ven-
lafaxine XR (n  469) and sertraline (n  4617) were
$344, $374, and $326, respectively. Treatment with ven-
lafaxine XR was associated with 11% higher (p  0.025)
total costs compared to treatment with mirtazapine.
There was no statistically significant difference in total
depression-related costs between mirtazapine and sertra-
line (p  0.072). Similar results were obtained when
pharmacy costs were used as a dependent variable in the
multivariate model.
CONCLUSIONS: Compared to sertraline and mirtazapine,
venlafaxine XR was associated with significantly higher
depression-related total costs. Treatment with mirtazapine
was associated with higher depression-related total costs,
but the results were not statistically significant.
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OBJECTIVE: Schizophrenia costs between $CDN 1.17 to
2.94 billion, annually. The objective of this analysis was
to quantify the costs of treatment for patients receiving
clozapine (CLZ), olanzapine (OLZ), quetiapine (QUE) or
risperidone (RIS) as antipsychotic monotherapy.
METHODS: CNOMSS is a prospective, longitudinal,
naturalistic study involving 456 patients from 32 com-
munity and academic sites across Canada. Patients com-
pleted a monthly resource-use questionnaire detailing the
quantity of health-care resources accessed during the pre-
vious month. This study included 316 patients (67 CLZ,
118 OLZ, 28 QUE, 103 RIS) who had used an atypical
antipsychotic as continuous monotherapy since entry
into the study. Each patient’s mean monthly cost of care
was determined. Analysis of covariance was used to com-
pare costs, adjusting for demographic and disease-spe-
cific factors.
RESULTS: The unadjusted cost of care per patient-
month was $2,305 for CLZ, $1,046 for OLZ, $644 for
QUE, and $533 for RIS. Inpatient costs were the greatest
contributors to total costs for CLZ (51%) and QUE pa-
tients (43%), while outpatient costs comprised the great-
est portion of OLZ (34%) and RIS (44%) treatment
costs. From the model, drug costs were higher in CLZ
($415, p  .001) and OLZ patients ($314, p  .001) ver-
sus RIS-treated patients ($145). No difference in drug
costs was detected between RIS and QUE ($160, p 
0.632). Adjusted lab/diagnostic costs (p  .001), psychi-
atric day care (p  0.013), psychiatric nursing (p 
0.001), specialists (p  0.031), and inpatient costs (p 
0.005) were greater in CLZ patients versus RIS-treated
patients. Compared to RIS, the adjusted cost of accessing
social workers was also greater for both CLZ (p 
0.003) and OLZ (p  0.091) patients.
CONCLUSION: The results of this analysis indicate that,
even after adjustment for demographics and severity,
treatment with clozapine is the most costly atypical
monotherapy, while from a budgetary perspective, ris-
peridone was the least expensive drug treatment.
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OBJECTIVE: The novel antipsychotics in comparison
with old ones turned out to have similar clinical efficacy,
produce less adverse effects, increase quality of life, re-
duce hospital stay with subsequent shift in resources to-
wards community care. However, in Poland drug costs
result in substantial percentage of direct health care costs
and cost-effectiveness of novel antipsychotics can be
questionable. A decision analysis model was used to eval-
uate potential clinical and economic consequences of us-
ing oral risperidone versus haloperidol in chronic schizo-
phrenic Polish patients.
METHODS: A decision analysis model based on a three
month Markov cycle tree was implemented through a
time horizon of five years. The probability parameters for
